Comparison of Resolute zotarolimus-eluting stents versus everolimus-eluting stents in patients with metabolic syndrome and acute myocardial infarction: propensity score-matched analysis.
暂无分享,去创建一个
M. Jeong | Y. Ahn | Young Jo Kim | M. Cho | C. Kim | S. Chae | T. Hong | I. Seong | J. Chae | K. Seung | Seung‐Jung Park | J. Bae | S. Rha | S. Hur | Sang Hyung Kim | M. Ji
[1] S. Windecker,et al. Safety and Efficacy of Resolute Zotarolimus-Eluting Stents Compared With Everolimus-Eluting Stents: A Meta-Analysis , 2015, Circulation. Cardiovascular interventions.
[2] I. Seong,et al. Everolimus-eluting Xience v/Promus versus zotarolimus-eluting resolute stents in patients with diabetes mellitus. , 2014, JACC. Cardiovascular interventions.
[3] G. Stone,et al. The prognostic importance of left ventricular function in patients with ST-segment elevation myocardial infarction: the HORIZONS-AMI trial , 2014, European heart journal. Acute cardiovascular care.
[4] H. Selker,et al. Factors Associated With Longer Time to Treatment for Patients With Suspected Acute Coronary Syndromes: A Cohort Study , 2014, Circulation. Cardiovascular quality and outcomes.
[5] M. Jeong,et al. One-Year Clinical Outcomes among Patients with Metabolic Syndrome and Acute Myocardial Infarction , 2013, Korean circulation journal.
[6] M. Jeong,et al. Association of metabolic syndrome and renal insufficiency with clinical outcome in acute myocardial infarction. , 2013, Metabolism: clinical and experimental.
[7] M. Banach,et al. Metabolic syndrome and renal disease. , 2013, International journal of cardiology.
[8] Nicholas A Peppas,et al. Recent advances in drug eluting stents. , 2013, International journal of pharmaceutics.
[9] Mark D. Huffman,et al. Presentation, management, and outcomes of 25 748 acute coronary syndrome admissions in Kerala, India: results from the Kerala ACS Registry. , 2013, European heart journal.
[10] Michael J Pencina,et al. Repeat Revascularization After Contemporary Percutaneous Coronary Intervention: An Evaluation of Staged, Target Lesion, and Other Unplanned Revascularization Procedures During the First Year , 2012, Circulation. Cardiovascular interventions.
[11] A. Coats,et al. Adherence to ethical standards in publishing scientific articles: a statement from the International Journal of Cardiology. , 2012, International journal of cardiology.
[12] Deepak L. Bhatt,et al. Short- and Long-Term Outcomes With Drug-Eluting and Bare-Metal Coronary Stents: A Mixed-Treatment Comparison Analysis of 117 762 Patient-Years of Follow-Up From Randomized Trials , 2012, Circulation.
[13] P. Serruys,et al. Stent Thrombosis With Everolimus-Eluting Stents: Meta-Analysis of Comparative Randomized Controlled Trials , 2012, Circulation. Cardiovascular interventions.
[14] J. W. Louwerenburg,et al. A randomized controlled trial in second-generation zotarolimus-eluting Resolute stents versus everolimus-eluting Xience V stents in real-world patients: the TWENTE trial. , 2012, Journal of the American College of Cardiology.
[15] K. Cao,et al. The angiographic and clinical outcomes after coronary stenting in patients with metabolic syndrome. , 2012, Atherosclerosis.
[16] P. Serruys,et al. Plaque composition and clinical outcomes in acute coronary syndrome patients with metabolic syndrome or diabetes. , 2012, JACC. Cardiovascular imaging.
[17] S. Goyal,et al. Impact of metabolic syndrome on re-stenosis development: Role of drug-eluting stents , 2012, Diabetes & vascular disease research.
[18] Jong Chun Park,et al. Comparison of paclitaxel-, sirolimus-, and zotarolimus-eluting stents in patients with acute ST-segment elevation myocardial infarction and metabolic syndrome. , 2011, Circulation journal : official journal of the Japanese Circulation Society.
[19] R. Whitbourn,et al. Impact of Polymer Formulations on Neointimal Proliferation After Zotarolimus-Eluting Stent With Different Polymers: Insights From the RESOLUTE Trial , 2011, Circulation. Cardiovascular interventions.
[20] P. Serruys,et al. The impact of patient and lesion complexity on clinical and angiographic outcomes after revascularization with zotarolimus- and everolimus-eluting stents: a substudy of the RESOLUTE All Comers Trial (a randomized comparison of a zotarolimus-eluting stent with an everolimus-eluting stent for percutan , 2011, Journal of the American College of Cardiology.
[21] Akiko Maehara,et al. A prospective natural-history study of coronary atherosclerosis. , 2011, The New England journal of medicine.
[22] Thomas D. Scott,et al. Predictors of reperfusion delay in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention from the HORIZONS-AMI trial. , 2010, The American journal of cardiology.
[23] Lawrence Joseph,et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. , 2010, Journal of the American College of Cardiology.
[24] P. Serruys,et al. Coronary stents: current status. , 2010, Journal of the American College of Cardiology.
[25] T. Naganuma,et al. Clinical predictors of culprit plaque rupture assessed on intravascular ultrasound in acute coronary syndrome. , 2010, Circulation journal : official journal of the Japanese Circulation Society.
[26] Volker Klauss,et al. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. , 2010, The New England journal of medicine.
[27] L. Pendyala,et al. The first-generation drug-eluting stents and coronary endothelial dysfunction. , 2009, JACC. Cardiovascular interventions.
[28] Ju Han Kim,et al. Differences in Clinical Outcomes Between Patients With ST-Elevation Versus Non-ST-Elevation Acute Myocardial Infarction in Korea , 2009, Korean circulation journal.
[29] Qi Zhang,et al. Impact of moderate or severe renal insufficiency on long-term outcomes in patients undergoing drug-eluting stent based coronary intervention. , 2009, International journal of cardiology.
[30] G. De Luca,et al. Percutaneous coronary intervention-related time delay, patient's risk profile, and survival benefits of primary angioplasty vs lytic therapy in ST-segment elevation myocardial infarction. , 2009, The American journal of emergency medicine.
[31] F. Burzotta,et al. Metabolic Syndrome Is a Poor Predictor of Outcome after Coronary Interventions in High-Risk Patients , 2008, Hypertension Research.
[32] P. Macfarlane,et al. Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies , 2008, The Lancet.
[33] J. Afilalo,et al. Symptom-to-door time in ST segment elevation myocardial infarction: overemphasized or overlooked? Results from the AMI-McGill study. , 2008, The Canadian journal of cardiology.
[34] J. Ottervanger,et al. The importance of left ventricular function for long-term outcome after primary percutaneous coronary intervention , 2008, BMC Cardiovascular Disorders.
[35] Y. van der Graaf,et al. Metabolic syndrome and the risk of new vascular events and all-cause mortality in patients with coronary artery disease, cerebrovascular disease, peripheral arterial disease or abdominal aortic aneurysm. , 2007, European heart journal.
[36] P. Serruys,et al. Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions , 2007, Circulation.
[37] Victor M Montori,et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. , 2007, Journal of the American College of Cardiology.
[38] H. Burt,et al. Drug-eluting stents: factors governing local pharmacokinetics. , 2006, Advanced drug delivery reviews.
[39] Ali H Mokdad,et al. Increasing prevalence of the metabolic syndrome among u.s. Adults. , 2004, Diabetes care.
[40] S. Grundy,et al. The metabolic syndrome , 2003, The Lancet.
[41] J. Ottervanger,et al. Time-to-treatment significantly affects the extent of ST-segment resolution and myocardial blush in patients with acute myocardial infarction treated by primary angioplasty. , 2004, European heart journal.
[42] H. Suryapranata,et al. Symptom-onset-to-balloon time and mortality in patients with acute myocardial infarction treated by primary angioplasty. , 2003, Journal of the American College of Cardiology.
[43] Jukka T Salonen,et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. , 2002, JAMA.
[44] J. W. Louwerenburg,et al. Complex patients treated with zotarolimus‐eluting resolute and everolimus‐eluting xience V stents in the randomized TWENTE trial: Comparison of 2‐year clinical outcome , 2015, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[45] J. Baron,et al. World Wide Web at: , 2001 .